A trial looking at a new drug called LY2940680 and paclitaxel for advanced cancer (HIPROC)

The research team found the best dose of taladegib to give in part 1 of this trial. They weren’t able to do part 2 because of problems with the supply of taladegib.

Trial design
This trial was for people who’d had treatment but their cancer had continued to grow. 

The first few people had the lowest dose of taladegib. As they didn’t have any serious side effects, the next few people had a higher dose. And so on, until they found the best dose to give. This is called a dose escalation study.

Results
A total of 16 people joined the trial. They all had taladegib and paclitaxel.

In total:

• 3 people had the lowest dose of taladegib
• 6 people had a medium dose of taladegib
• 7 people had the higher dose of taladegib

 People who had the lowest dose or medium dose of taladegib didn’t have any side serious side effects. But some people who had the higher dose did. So the team decided the medium dose was the best one to use. 

The main serious side effect of those in the higher dose group was numbness and tingling in the hands and feet. This is called peripheral neuropathy.

The trial team also looked at how well treatment worked in 14 of the people who took part.

It’s hard to draw any firm conclusions because of the small number of people. But the results showed that, 4 months after joining the trial, the cancer had:

• got a bit smaller in 4 people
• stayed the same in 6 people
• continued to grow in 4 people

Conclusion
The research team concluded that they found the best dose of taladegib to give alongside paclitaxel. 

Where this information comes from    
We have based this summary on information from the research team. As far as we are aware, the information they sent us has not been reviewed independently (peer reviewed ) or published in a medical journal yet. The figures we quote above were provided by the research team. We have not analysed the data ourselves.